Bibliografia UJ CM

1/11
Aleksandra Wieczorek, Carla Manzitti, Alberto Garaventa, Juliet Gray, Vassilios Papadakis, Dominique Valteau-Couanet, Katarzyna Zachwieja, Ulrike Poetschger, Ingrid Pribill, Stefan Fiedler, Ruth Ladenstein, Holger N. Lode.
Clinical phenotype and management of severe neurotoxicity observed in patients with neuroblastoma treated with dinutuximab beta in clinical trials.
Cancers
2022 : Vol. 14, nr 8, il., bibliogr. 33 poz., abstr., sum.
Autor korespondencyjny: Holger N. Lode.
Open Access Creative Commons Attribution License CC-BY 4.0.
e-ISSN: 2072-6694
AZ
ORG
AIF
IF: 5.200
Adres url:
Streszczenie w PubMed:
2/11
Angela Bellini, Ulrike Potschger, Virginie Bernard, Eve Lapouble, Sylvain Baulande, Peter F. Ambros, Nathalie Auger, Klaus Beiske, Marie Bernkopf, David R. Betts, Jaydutt Bhalshankar, Nick Bown, Katleen de Preter, Nathalie Clement, Valerie Combaret, Jaime Font de Mora, Sally L. George, Irene Jimenez, Marta Jeison, Barbara Marques, Tommy Martinsson, Katia Mazzocco, Martina Morini, Annick Muhlethaler-Mottet, Rosa Noguera, Gaelle Pierron, Maria Rossing, Sabine Taschner-Mandl, Nadine Van Roy, Ales Vicha, Louis Chesler, Walentyna Balwierz, Victoria Castel, Martin Elliott, Per Kogner, Genevieve Laureys, Roberto Luksch, Josef Malis, Maja Popovic-Beck, Shifra Ash, Olivier Delattre, Dominique Valteau-Couanet, Deborah A. Tweddle, Ruth Ladenstein, Gudrun Schleiermacher.
Frequency and prognostic impact of ALK amplifications and mutations in the European Neuroblastoma Study Group (SIOPEN) High-Risk Neuroblastoma Trial (HR-NBL1).
Journal of Clinical Oncology
2021 : Vol. 39, nr 30, s. 3377-3390, il., bibliogr. 56 poz., abstr.
Autor korespondencyjny: Gudrun Schleiermacher.
Open Access Creative Commons Attribution License CC-BY 4.0.
p-ISSN: 0732-183X
e-ISSN: 1527-7755
AZ
ORG
AIF
IF: 50.739
Adres url:
Streszczenie w PubMed:
3/11
Alberto Garaventa, Ulrike Poetschger, Dominique Valteau-Couanet, Roberto Luksch, Victoria Castel, Martin Elliott, Shifra Ash, Godfrey C.F. Chan, Genevieve Laureys, Maja Beck-Popovic, Kim Vettenranta, Walentyna Balwierz, Henrik Schroeder, Cormac Owens, Maja Cesen, Vassilios Papadakis, Toby Trahair, Gudrun Schleiermacher, Peter Ambros, Stefania Sorrentino, Andrew D.J. Pearson, Ruth Lydia Ladenstein.
Randomized Trial of Two Induction Therapy Regimens for High-Risk Neuroblastoma : HR-NBL1.5 International Society of Pediatric Oncology European Neuroblastoma Group Study.
Journal of Clinical Oncology
2021 : Vol. 39, nr 23, s. 2552-2563
Autor korespondencyjny: Ruth Lydia Ladenstein.
p-ISSN: 0732-183X
e-ISSN: 1527-7755
AZ
ORG
AIF
IF: 50.739
Adres url:
Streszczenie w PubMed:
4/11
Keith Holmes, Ulrike Potschger, Andrew D.J. Pearson, Sabine Sarnacki, Giovanni Cecchetto, Javier Gomez-Chacon, Roly Squire, Enrique Freud, Adam Bysiek, Lucas E. Matthyssens, Martin Metzelder, Tom Monclair, Jakob Stenman, Michal Rygl, Lars Rasmussen, Jean-Marc Joseph, Sabine Irtan, Stefano Avanzini, Jan Godzinski, Kristin Bjornland, Martin Elliott, Roberto Luksch, Victoria Castel, Shifra Ash, Walentyna Balwierz, Genevieve Laureys, Ellen Ruud, Vassilios Papadakis, Josef Malis, Cormac Owens, Henrik Schroeder, Maja Beck-Popovic, Toby Trahair, Ana Forjaz De Lacerda, Peter F. Ambros, Mark N. Gaze, Kieran McHugh, Dominique Valteau-Couanet, Ruth Lydia Ladenstein.
Influence of Surgical Excision on the Survival of Patients With Stage 4 High-Risk Neuroblastoma : A Report From the HR-NBL1/SIOPEN Study.
Journal of Clinical Oncology
2020 : Vol. 38, nr 25, s. 2902-2915
Autor korespondencyjny: Ruth Lydia Ladenstein.
p-ISSN: 0732-183X
AZ
ORG
AIF
IF: 44.544
Adres url:
Streszczenie w PubMed:
DOI:
5/11
Ruth Lydia Ladenstein, Ulrike Poetschger, Dominique Valteau-Couanet, Juliet Gray, Roberto Luksch, Walentyna Balwierz, Victoria Castel, Shifra Ash, Maja Beck Popovic, Genevieve Laureys, Godfrey Chi-Fung Chan, Ellen Ruud, Kim Vettenranta, Cormac Owens, Henrik Schroeder, Peter F. Ambros, Sabine Sarnacki, Tom Boterberg, Holger N. Lode.
Risk factors in the HR-NBL-1/SIOPEN study in patients receiving dinutuximab beta (DB) based immunotherapy.
Journal of Clinical Oncology
2020 : Vol. 38, nr 15 suppl., abtr. 10536
2020 ASCO Annual Meeting I.
p-ISSN: 0732-183X
SZZ
SIF
Adres url:
6/11
Lydia Ruth Ladenstein, Ulrike Poetschger, Dominique Valteau-Couanet, Juliet Gray, Roberto Luksch, Walentyna Balwierz, Victoria Castel, Shifra Ash, Maja Beck Popovic, Genevieve Laureys, Godfrey Chi Fung Chan, Ellen Ruud, Kim Vettenranta, Cormac Owens, Henrik Schroeder, Hans Loibner, Peter F. Ambros, Sabine Sarnacki, Tom Boterberg, Holger N. Lode.
Randomization of dose-reduced subcutaneous interleukin-2 (scIL2) in maintenance immunotherapy (IT) with anti-GD2 antibody dinutuximab beta (DB) long-term infusion (LTI) in front-line high-risk neuroblastoma patients: Early results from the HR-NBL1/SIOPEN trial.
Journal of Clinical Oncology
2019 : Vol. 37, nr 15, suppl., abstr. 10013
2019 ASCO Annual Meeting I.
p-ISSN: 0732-183X
SZZ
SIF
7/11
Daniel A. Morgenstern, Ulrike Potschger, Lucas Moreno, Vassilios Papadakis, Cormac Owens, Shifra Ash, Claudia Pasqualini, Roberto Luksch, Alberto Garaventa, Adela Canete, Martin Elliot, Aleksandra Wieczorek, Genevieve Laureys, Per Kogner, Josef Malis, Ellen Ruud, Maja Beck-Popovic, Gudrun Schleiermacher, Dominique Valteau-Couanet, Ruth Ladenstein.
Risk stratification of high-risk metastatic neuroblastoma: A report from the HR-NBL-1/SIOPEN study.
Pediatric Blood & Cancer
2018 : Vol. 65, nr 11 art. no. e27363, s. 1-9, il., bibliogr. 34 poz., abstr.
Autor korespondencyjny: Ulrike Potschger.
p-ISSN: 1545-5009
AZ
ORG
AIF
IF: 2.486
Adres url:
Streszczenie w PubMed:
8/11
Ruth Ladenstein, Ulrike Pötschger, Andrew D.J. Pearson, Penelope Brock, Roberto Luksch, Victoria Castel, Isaac Yaniv, Vassilios Papadakis, Genevieve Laureys, Josef Malis, Walentyna Balwierz, Ellen Ruud, Per Kogner, Henrik Schroeder, Ana Forjaz De Lacerda, Maja Beck-Popovic, Pavel Bician, Miklós Garami, Toby Trahair, Adela Canete, Peter F. Ambros, Keith Holmes, Mark Gaze, Günter Schreier, Alberto Garaventa, Gilles Vassal, Jean Michon, Dominique Valteau-Couanet.
Busulfan and melphalan versus carboplatin, etoposide, and melphalan as high-dose chemotherapy for high-risk neuroblastoma (HR-NBL1/SIOPEN): an international, randomised, multi-arm, open-label, phase 3 trial.
Lancet. Oncology
2017 : Vol. 18, nr 4, s. 500-514, il., bibliogr. 30 poz., sum.
Autor korespondencyjny: Ruth Ladenstein.
p-ISSN: 1470-2045
AZ
ORG
AIF
IF: 36.418
Adres url:
Streszczenie w PubMed:
9/11
Ruth Ladenstein, Ulrike Poetschger, Roberto Luksch, Penelope Brock, Victoria Castel, Isaac Yaniv, Vassilios Papadakis, Genevieve Laureys, Josef Malis, Walentyna Balwierz, Ellen Ruud, Per Kogner, Henrik Schroeder, Ana Forjaz De Lacerda, Maja Beck-Popovic, Pavel Bician, Miklos Garami, Toby Trahair, Peter Ambros, Andrew D.J. Pearson, Dominique Valteau-Couanet, SIOP Europe Neuroblastoma Group.
Major results from the HR-NBL1/SIOPEN trial for high risk neuroblastoma.
Pediatric Blood & Cancer
2012 : Vol. 59, nr 6, s. 988-989, abstr. O069
44th Congress of the International Society of Paediatric Oncology (SIOP), London, United Kingdom, 5th-8th October, 2012
p-ISSN: 1545-5009
SZZ
SIF
10/11
Ruth Ladenstein, Ulrike Poetschger, Roberto Luksch, Penelope Brock, Victoria Castel, Isaac Yaniv, Vassilios Papadakis, Genevieve Laureys, Josef Malis, Walentyna Balwierz, Ellen Ruud, Per Kogner, Henrik Schroeder, Ana Forjaz De Lacerda, Maja Beck-Popovic, Pavel Bician, Miklos Garami, Toby Trahair, Andrew D.J. Pearson, Dominique Valteau-Couanet.
Busulphan-melphalan is the superior myeloablative therapy (MAT) for high-risk neuroblastoma: Results from the HR-NBL1/SIOPEN Trial.
Pediatric Blood & Cancer
2011 : Vol. 57, nr 5, s. 733, abstr. O103
43rd Congress of the International Society of Pediatric Oncology (SIOP) 2011, Auckland, New Zealand, 28th-30th October, 2011
p-ISSN: 1545-5009
SZZ
SIF
11/11
Ruth Ladenstein, Dominique Valteau-Couanet, Penelope Brock, Isaac Yaniv, Victoria Castel, Genevieve Laureys, Josef Malis, Vassilios Papadakis, Ana Lacerda, Ellen Ruud, Per Kogner, Miklos Garami, Walentyna Balwierz, Henrik Schroeder, Maja Beck-Popovic, Gunter Schreier, David Machin, Ulrike Potschger, Andrew Pearson.
Randomized Trial of prophylactic granulocyte colony-stimulating factor during rapid COJEC induction in pediatric patients with high-risk neuroblastoma : the European HR-NBL1/SIOPEN study.
Journal of Clinical Oncology
2010 : Vol. 28, nr 21, s. 3516-3524, il., bibliogr. 55 poz.
p-ISSN: 0732-183X
AZ
ORG
AIF
IF: 18.970
Wyświetl ponownie stosując format:

Wyświetl/ukryj etykiety | Wyświetlenie wyników w wersji do druku | Pobranie pliku do edytora | Nowe wyszukiwanie | Biblioteka Medyczna UJ